These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10592777)

  • 1. [Hypertension in obesity: its epidemiology, physiopathology and treatment efforts].
    Sharma AM; Moeller T; Engeli S
    Dtsch Med Wochenschr; 1999 Nov; 124(45):1337-41. PubMed ID: 10592777
    [No Abstract]   [Full Text] [Related]  

  • 2. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?
    Straznicky N; Grassi G; Esler M; Lambert G; Dixon J; Lambert E; Jordan J; Schlaich M; ;
    J Hypertens; 2010 Apr; 28(4):637-43. PubMed ID: 20125037
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant hypertension: an overview of evaluation and treatment.
    Sarafidis PA; Bakris GL
    J Am Coll Cardiol; 2008 Nov; 52(22):1749-57. PubMed ID: 19022154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of obesity-related hypertension].
    Skoczylas A
    Wiad Lek; 2006; 59(5-6):403-6. PubMed ID: 17017491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy refractory hypertension: mask helped where drugs failed].
    Stiefelhagen P
    MMW Fortschr Med; 2005 Jun; 147(25):10. PubMed ID: 16038331
    [No Abstract]   [Full Text] [Related]  

  • 8. European Society of Hypertension Working Group on Obesity: background, aims and perspectives.
    Jordan J; Engeli S; Redon J; Sharma AM; Luft FC; Narkiewicz K; Grassi G;
    J Hypertens; 2007 Apr; 25(4):897-900. PubMed ID: 17351387
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypertension and obesity.
    Dustan HP
    Prim Care; 1991 Sep; 18(3):495-507. PubMed ID: 1946785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?
    Ballantyne CM
    Crit Pathw Cardiol; 2007 Jun; 6(2):41-5. PubMed ID: 17667863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms linking obesity to hypertension.
    Dorresteijn JA; Visseren FL; Spiering W
    Obes Rev; 2012 Jan; 13(1):17-26. PubMed ID: 21831233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive therapy in the obese hypertensive patient.
    Chrostowska M; Szczech R; Narkiewicz K
    Curr Opin Nephrol Hypertens; 2006 Sep; 15(5):487-92. PubMed ID: 16914960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diethylpropion hydrochloride (Tenuate Dospan) in combination with hypotensive agents in the treatment of obesity associated with hypertension.
    Seedat YK; Reddy J
    Curr Ther Res Clin Exp; 1974 May; 16(5):398-413. PubMed ID: 4209056
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
    Doggrell SA
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):119-25. PubMed ID: 15834464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current options for the treatment of resistant hypertension.
    Ahmed MI; Pisoni R; Calhoun DA
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1385-93. PubMed ID: 19900021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity: new perspectives and pharmacotherapies.
    Palamara KL; Mogul HR; Peterson SJ; Frishman WH
    Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure: effects upon plasma insulin levels and association with changes in blood pressure and serum lipids.
    Fagerberg B; Berglund A; Andersson OK; Berglund G
    J Hypertens; 1992 Sep; 10(9):1053-61. PubMed ID: 1328365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertension in obese patients.
    Kidambi S; Kotchen TA
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):163-75. PubMed ID: 23579967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aorta and resistant hypertension.
    Williams B
    J Am Coll Cardiol; 2009 Feb; 53(5):452-4. PubMed ID: 19179204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.